CPC A61K 47/549 (2017.08) [A61K 47/6807 (2017.08); A61K 47/6851 (2017.08); A61K 48/005 (2013.01); A61P 35/00 (2018.01); C07K 14/4747 (2013.01); C07K 14/52 (2013.01); C07K 16/44 (2013.01); C12N 15/111 (2013.01); C12N 15/1135 (2013.01); C12N 15/87 (2013.01); A61K 48/00 (2013.01); A61K 48/0025 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/77 (2013.01); C07K 2319/33 (2013.01); C12N 15/113 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01); C12N 2310/3181 (2013.01); C12N 2310/3513 (2013.01); C12N 2320/32 (2013.01)] | 22 Claims |
1. A composition comprising a non-covalent complex of (a) an antibody or antigen-binding fragment thereof, and (b) an mRNA,
wherein the antibody or antigen-binding fragment thereof comprises heavy chain variable region (VH) complementarity determining regions (CDRs) having the amino acid sequences of SEQ ID NO:16, SEQ ID NO:17, and SEQ ID NO:18, and light chain variable region (VL) CDRs having the amino acid sequences of SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26.
|